Cheryl Arrowsmith

Cheryl H. Arrowsmith is a Canadian-based structural biologist and is the Chief Scientist at the Toronto laboratory of the Structural Genomics Consortium. Her contributions to protein structural biology includes the use of NMR and X-ray crystallography to pursue structures of proteins on a proteome wide scale.

She received her Ph.D. in chemistry at the University of Toronto in 1987 and post-doctoral training at Stanford University working with Professor Oleg Jardetzky. One of her areas of interest is the tumour suppressor p53 and related proteins.

Her current research is to determine the 3-dimensional structures of human proteins of therapeutic relevance to diseases such as cancer, malaria and diabetes metabolic disorders by structural proteomics. One main advantage of this approach is economy of scale, although the scientific value of some resultant structures is at times questioned.[1]

Dr. Arrowsmith was a co-founder of Toronto-based biotech company Affinium Pharmaceuticals in 2000.

Dr Arrowsmith was named a Fellow of the American Association for the Advancement of Science (AAAS) in 2015.[2]

External links

References

  1. ↑ Chandonia JM, Brenner SE (January 2006). "The impact of structural genomics: expectations and outcomes". Science. 311 (5759): 347–51. doi:10.1126/science.1121018. PMID 16424331.
  2. ↑ http://medicine.utoronto.ca/news/arrowsmith-named-aaas-fellow
This article is issued from Wikipedia - version of the 11/6/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.